You have full text access to this Open Access content

Cancer Medicine

Cover image for Vol. 2 Issue 3

June 2013

Volume 2, Issue 3

Pages i–ii, 267–419

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. Cancer Biology
    4. Clinical Cancer Research
    5. Cancer Prevention
    1. You have full text access to this Open Access content
      Issue Information (pages i–ii)

      Article first published online: 4 JUN 2013 | DOI: 10.1002/cam4.99

  2. Cancer Biology

    1. Top of page
    2. Issue Information
    3. Cancer Biology
    4. Clinical Cancer Research
    5. Cancer Prevention
    1. Original Research

      You have full text access to this OnlineOpen article
      Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells (pages 267–276)

      Hideki Kitajima, Yuji Komizu, Hideaki Ichihara, Koichi Goto and Ryuichi Ueoka

      Article first published online: 22 MAR 2013 | DOI: 10.1002/cam4.67

      Thumbnail image of graphical abstract

      Remarkable inhibitory effects of hybrid liposomes (HL-23) composed of l-α-dimyristoylphosphatidylcholine and polyoxyethylene(23) dodecyl ether on the metastatic growth of murine osteosarcoma (LM8) cells were obtained in vitro. HL-23 significantly inhibited the primary tumor growth of LM8 cells in the homograft mouse models along with apoptosis. Furthermore, HL-23 drastically inhibited the lung metastasis of LM8 cells in the mouse models through the inhibition of invasion.

    2. You have full text access to this OnlineOpen article
      Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab (pages 277–285)

      Timothy J. Price, Jennifer E. Hardingham, Chee K. Lee, Amanda R. Townsend, Joseph W. Wrin, Kate Wilson, Andrew Weickhardt, Robert J. Simes, Carmel Murone and Niall C. Tebbutt

      Article first published online: 25 MAR 2013 | DOI: 10.1002/cam4.75

      Thumbnail image of graphical abstract

      Phosphatase and tensin homologue (PTEN) remains controversial as a predictive and prognostic marker. There also remains uncertainty as to the best method to assess PTEN status. Here, we use PTEN copy number and assess the association of outcome and PTEN loss, as defined by copy number variation.

    3. You have full text access to this OnlineOpen article
      Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma (pages 286–295)

      Kumi Kawano, Yoshiyuki Hattori, Hiroshi Iwakura, Takashi Akamizu and Yoshie Maitani

      Article first published online: 2 APR 2013 | DOI: 10.1002/cam4.76

      Thumbnail image of graphical abstract

      In a transgenic mouse model of neuroblastoma with bilateral adrenal gland tumors, combination therapy with doxorubicin (DXR) and gefitinib strongly inhibited tumor growth than treatment with DXR or gefitinib alone, as assessed by magnetic resonance imaging.

    4. You have full text access to this OnlineOpen article
      EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients (pages 296–304)

      Claire Villalva, Valérie Duranton-Tanneur, Karline Guilloteau, Fanny Burel-Vandenbos, Michel Wager, Jérôme Doyen, Pierre Marie Levillain, Denys Fontaine, Hélène Blons, Florence Pedeutour and Lucie Karayan-Tapon

      Article first published online: 23 APR 2013 | DOI: 10.1002/cam4.82

      Thumbnail image of graphical abstract

      This study of EGFR, KRAS, BRAF and HER-2 mutational status in 77 brain metastases from non-small cell lung cancer (NSCLC) reveals a low frequency of EGFR mutations whereas KRAS mutations are as frequent as in primitive NSCLC. These results raise the question of the variability of brain metastatic potential of NSCLC cells in relationship to mutation patterns.

    5. You have full text access to this OnlineOpen article
      Aromatase in human liver and its diseases (pages 305–315)

      Shuko Hata, Yasuhiro Miki, Ryoko Saito, Kazuyuki Ishida, Mika Watanabe and Hironobu Sasano

      Article first published online: 30 APR 2013 | DOI: 10.1002/cam4.85

      Thumbnail image of graphical abstract

      In this study, we first immunolocalized aromatase using immunohistochemistry in patients with liver cirrhosis, steatosis, hepatitis, hepatocellular carcinoma (HCC), and metastasis liver carcinoma (MLC) in order to study the detailed status of intrahepatic aromatase. Aromatase immunoreactivity was predominantly detected in non-neoplastic hepatocytes around tumor cells. These findings all indicated that carcinoma cells, whether metastatic or primary, induced aromatase expression in adjacent normal hepatocytes through the potential soluble aromatase inducible factors in human hepatic microenvironments.

  3. Clinical Cancer Research

    1. Top of page
    2. Issue Information
    3. Cancer Biology
    4. Clinical Cancer Research
    5. Cancer Prevention
    1. Original Research

      You have full text access to this OnlineOpen article
      A phase I study of ABT-510 plus bevacizumab in advanced solid tumors (pages 316–324)

      Hope E. Uronis, Stephanie M. Cushman, Johanna C. Bendell, Gerard C. Blobe, Michael A. Morse, Andrew B. Nixon, Andrew Dellinger, Mark D. Starr, Haiyan Li, Kellen Meadows, Jon Gockerman, Herbert Pang and Herbert I. Hurwitz

      Article first published online: 21 MAR 2013 | DOI: 10.1002/cam4.65

      Thumbnail image of graphical abstract

      This study was designed to evaluate the effects of dual inhibition of the vascular endothelial growth factor axis and the thrombospondin axis on refractory solid tumors. We found signs of clinical activity in patients with various tumor types, though whether this was related to one or both agents is not known. We also found that plasma levels of stromal-derived factor 1 (SDF-1) and placental growth factor (PlGF) were elevated on combination therapy, consistent with prior published reports. These data suggest that combination anti-angiogenesis therapies may be clinically useful.

    2. You have full text access to this OnlineOpen article
      Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma (pages 325–333)

      Dominique Werner, Akin Atmaca, Claudia Pauligk, Anette Pustowka, Elke Jäger and Salah-Eddin Al-Batran

      Article first published online: 2 APR 2013 | DOI: 10.1002/cam4.77

      Thumbnail image of graphical abstract

      This is a phase I study for determining the recommended dose of daily everolimus administered orally in combination with mitomycin C, administered every 3 weeks to patients with metastatic gastric cancer or adenocarcinoma of the esophagogastric junction.

    3. You have full text access to this OnlineOpen article
      A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion (pages 334–342)

      Michelle Haslinger, Valerie Francescutti, Kristopher Attwood, Judith Andrea McCart, Marwan Fakih, John M. Kane III and Joseph J. Skitzki

      Article first published online: 16 APR 2013 | DOI: 10.1002/cam4.80

      Thumbnail image of graphical abstract

      In the contemporary setting, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) are associated with a low mortality and improved survival. When present, complications are associated with a decreased overall survival. This treatment modality should be considered within the context of multidisciplinary care for select peritoneal carcinomatosis patients.

    4. You have full text access to this OnlineOpen article
      Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico (pages 343–350)

      Ana Patricia Ortiz, Orquidea Frías, Javier Pérez, Fernando Cabanillas, Lisa Martínez, Carola Sánchez, David E. Capó-Ramos, Carmen González-Keelan, Edna Mora and Erick Suárez

      Article first published online: 18 APR 2013 | DOI: 10.1002/cam4.78

      Thumbnail image of graphical abstract

      This clinic-based study aimed to evaluate the impact of Breast cancer (BC) molecular subtypes in on survival in Puerto Rico. Consistent to results in other populations, the triple-negative subtype and HER-2+ tumors were associated with decreased survival.

    5. You have full text access to this OnlineOpen article
      Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer (pages 351–359)

      Anne Tsao, Edwin Pun Hui, Rosalyn Juergens, Shanthi Marur, Tan Eng Huat, Goh Boon Cher, Ruey-Long Hong, Waun Ki Hong and Anthony Tak-Cheung Chan

      Article first published online: 18 APR 2013 | DOI: 10.1002/cam4.79

      Thumbnail image of graphical abstract

      TAS-106 was reasonably tolerated in patients with platinum-failure HNSCC and NPC with the 24-h continuous infusion administration schedule; however, there was no anti-tumor efficacy seen with TAS-106 monotherapy. Future studies will focus on TAS-106 combinations and mechanisms of drug resistance.

    6. You have full text access to this OnlineOpen article
      A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial (pages 360–366)

      Siow Ming Lee and Allan Hackshaw

      Article first published online: 24 APR 2013 | DOI: 10.1002/cam4.74

      Thumbnail image of graphical abstract

      We performed a retrospective analysis of non-small-cell lung cancer patients from a double-blind phase III trial of thalidomide versus placebo, in addition to standard chemotherapy. Among 150 patients with squamous cell cancer who had stable disease or complete/partial response after completing the second chemotherapy cycle, there was a 25% reduction in the death rate and 31% reduction in the risk of progressing or dying. We describe a potentially effective treatment strategy, in which a patient group is enriched using both histology and an early assessment of response during standard chemotherapy, and where a new agent is given for the remainder of chemotherapy and as maintenance.

  4. Cancer Prevention

    1. Top of page
    2. Issue Information
    3. Cancer Biology
    4. Clinical Cancer Research
    5. Cancer Prevention
    1. Review

      You have full text access to this OnlineOpen article
      Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis (pages 367–390)

      Hung N. Luu, Kristina R. Dahlstrom, Patricia Dolan Mullen, Helena M. VonVille and Michael E. Scheurer

      Article first published online: 21 APR 2013 | DOI: 10.1002/cam4.83

      Thumbnail image of graphical abstract

      The selection of a screening test is important to detect clinically relevant cases of Human papillomavirus (HPV) infection while avoiding the unnecessary cost, stress and compromise of the cervix to patients associated with over-treating mild cytological abnormalities. Given the clinical relevance and importance of cervical cancer worldwide, our results support the use of Hybrid Capture II (HCII) in cervical screening programs.

    2. Original Research

      You have full text access to this OnlineOpen article
      Adenoma detection in patients undergoing a comprehensive colonoscopy screening (pages 391–402)

      Gottumukkala S. Raju, Vikram Vadyala, Rebecca Slack, Somashekar G. Krishna, William A. Ross, Patrick M. Lynch, Robert S. Bresalier, Ernest Hawk and John R. Stroehlein

      Article first published online: 20 APR 2013 | DOI: 10.1002/cam4.73

      Thumbnail image of graphical abstract

      A comprehensive colonoscopy-screening program results in high-quality screening with high detection of adenomas, advanced adenomas, serrated adenomas, and multiple adenomas.

    3. You have full text access to this OnlineOpen article
      Cancer survival disparities by health insurance status (pages 403–411)

      Xiaoling Niu, Lisa M. Roche, Karen S. Pawlish and Kevin A. Henry

      Article first published online: 8 MAY 2013 | DOI: 10.1002/cam4.84

      Thumbnail image of graphical abstract

      In New Jersey, for many common cancers, uninsured and Medicaid insured patients have significantly higher risks of death than privately insured patients even after adjustment for other demographic and clinical factors. While ensuring that everyone has adequate health insurance is an important step, additional measures must be taken to address cancer survival disparities.

    4. You have full text access to this OnlineOpen article
      IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan (pages 412–419)

      Daisuke Asai, Toshihiko Imamura, So-ichi Suenobu, Akiko Saito, Daiichiro Hasegawa, Takao Deguchi, Yoshiko Hashii, Kimikazu Matsumoto, Hirohide Kawasaki, Hiroki Hori, Akihiro Iguchi, Yoshiyuki Kosaka, Koji Kato, Keizo Horibe, Keiko Yumura-Yagi, Junichi Hara and Megumi Oda, The Japan Association of Childhood Leukemia Study (JACLS)

      Article first published online: 9 MAY 2013 | DOI: 10.1002/cam4.87

      Thumbnail image of graphical abstract

      We conducted genetic analyses of IKZF1 deletion, point mutation of JAK2 exon 16, 17, and 21, CRLF2 expression, the presence of P2RY8-CRLF2 fusion and F232C mutation in CRLF2 in 202 pediatric BCP-ALL patients newly diagnosed and registered in Japan Childhood Leukemia Study ALL02 protocol to find out if IKZF1 deletion had reduced event-free survival and overall survival. JAK2 mutations and P2RY8-CRLF2 fusion were rarely detected. IKZF1 deletion was identified as adverse prognostic factor even in pediatric BCP-ALL showing good response to PSL.

SEARCH

SEARCH BY CITATION